Baxter International has agreed for merger & acquisition for Chatham Therapeutics for $70 million.
Baxter will acquire all of Chatham’s outstanding membership interests.
As a result of the transaction, Baxter will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.
Baxter obtains broad access to Chatham’s gene therapy platform, including the previously partnered hemophilia B (FIX) program, a preclinical hemophilia A (FVIII) program, and the potential future application to additional hemophilia treatments.
Baxter will make an initial payment of $70 million to acquire all of the outstanding membership interests of Chatham.
Baxter may make additional payments in the future based on specified development, regulatory and commercial milestones.
For further deal information visit Current Agreements (subscription required)
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
Report: Merger and Acquisition Terms and Agreements
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity